Cytori Therapeutics today announced its appointment of Clyde W. Shores as executive vice president of marketing and sales for the company, where he will lead global strategic marketing initiatives.

Shores will prepare the company for launch of sales of its next-generation Celution® One System, and will oversee strategy and initiatives to drive adoption and use of Cytori’s existing products, including the Celution® 800 and PureGraft™ Systems, as well as StemSource® cell and tissue banking.

In addition, Shores’ role positions him as responsible for laying the foundation for new regional and indication-based claims for the company’s existing products in both the European Union and the United States.

Shores’ 27 years experience in medical marketing and sales includes involvement in the launch and marketing of multiple innovative medical products. His experience gave him a fundamental understanding of the potential for stem cell pharmaceutical and devices, as well as marketing and sales angles for commercializing innovative therapeutics.

“Cytori has undergone an extensive search for the ideal leader of its marketing team,” Marc H. Hedrick, president of Cytori stated in the press release. “With his background in cell therapy, medical devices and pharmaceuticals, Clyde is uniquely qualified to drive our marketing efforts as we continue to lead the way in regenerative medicine. His entrepreneurial spirit, combined with broad experience with high growth products and industries, will allow him to integrate seamlessly with the existing culture at Cytori and add tremendous value to our marketing and sales teams.”

Shores’ most recently served as vice president of Global Marketing for Baxter International’s Renal Business. He has also worked for Abbott Laboratories, Amgen, Prometheus Laboratories and deCODE Genetics.

For more information visit